<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626751</url>
  </required_header>
  <id_info>
    <org_study_id>HZNP-HZN-825-302</org_study_id>
    <secondary_id>2021-006271-42</secondary_id>
    <nct_id>NCT05626751</nct_id>
  </id_info>
  <brief_title>An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)</brief_title>
  <official_title>A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Pharma Ireland, Ltd., Dublin Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma Ireland, Ltd., Dublin Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label&#xD;
           treatment with HZN-825 in participants with diffuse cutaneous systemic sclerosis, as&#xD;
           measured by change from both baselines in forced vital capacity percent (FVC %)&#xD;
           predicted.&#xD;
&#xD;
        2. The primary safety objective is to examine the safety and tolerability of 52 weeks of&#xD;
           open-label treatment with HZN-825, inclusive of, but not limited to, adverse events&#xD;
           (AEs), serious AEs (SAEs) and the adverse event of special interest (AESI), from Day 1&#xD;
           to 4 weeks after last dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, repeat-dose, multicenter extension trial of HZNP-HZN-825-301.&#xD;
      Participants who complete the double-blind Treatment Period (Week 52) in Trial&#xD;
      HZNP-HZN-825-301 will be eligible to enter this 52-week extension trial. Participants&#xD;
      entering this extension trial will complete the Week 52 Visit activities in HZNP-HZN-825-301&#xD;
      and will not complete the Safety Follow-up Visit 4 weeks after the last dose of trial drug in&#xD;
      HZNP-HZN-825-301.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2022</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from trial baseline, defined as the latest measurement prior to the first dose of HZN-825 in FVC % predicted</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>As measured by a pulmonary function test called a spirometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from HZN-825 Baseline, defined as the latest measurement prior to the first dose of HZN-825 in either trial HZNP-HZN-825-301 or this extension trial in FVC % predicted</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>As measured by a pulmonary function test called a spirometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Day 1 to Week 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events of special interest (AESI) orthostatic hypotension</measure>
    <time_frame>Day 1 to Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and frequency of use of concomitant medication</measure>
    <time_frame>Day 1 to Week 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from trial baseline in vital signs as reported as TEAEs</measure>
    <time_frame>Day 1 to Week 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from HZN-825 baseline in vital signs as reported as TEAEs</measure>
    <time_frame>Day 1 to Week 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from trial baseline in abnormal and clinically significant 12-lead electrocardiogram (ECG) measurements.</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Clinically significant changes in ECGs is defined as any clinical significant difference in heart rate, RR interval, PR interval, QRS, and QT interval corrected using Fridericia's formula (QTcF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from HZN-825 trial baseline in abnormal and clinically significant 12-lead ECG measurements.</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Clinically significant changes in ECGs is defined as any clinical significant difference in heart rate, RR interval, PR interval, QRS, and QT interval corrected using Fridericia's formula (QTcF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from trial baseline in abnormal laboratory test results</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Clinically significant lab values in serum chemistry, hematology, lipids, coagulation tests and urinalyses will be assessed (including Grade 3 or higher per common terminology criteria for adverse events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from HZN-825 baseline in abnormal laboratory test results</measure>
    <time_frame>Day 1 to Week 56</time_frame>
    <description>Clinically significant lab values in serum chemistry, hematology, lipids, coagulation tests and urinalyses will be assessed (including Grade 3 or higher per common terminology criteria for adverse events)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <condition>Sclerosis, Systemic</condition>
  <arm_group>
    <arm_group_label>HZN-825</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HZN-825 will be administered by mouth (PO) twice daily (BID) for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HZN-825</intervention_name>
    <description>HZN-825 will be administered BID for 52 weeks</description>
    <arm_group_label>HZN-825</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        1. Completed the double-blind Treatment Period (Week 52) in Trial HZNP-HZN-825-301;&#xD;
        participants prematurely discontinued from trial drug in Trial HZNP-HZN-825-301 for reasons&#xD;
        other than safety or toxicity can be included at the discretion of the Investigator after&#xD;
        completing Trial HZNP-HZN-825-301 scheduled visits, including Week 52 assessments.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Anticipated use of another investigational agent for any condition during the course&#xD;
             of the trial.&#xD;
&#xD;
          2. Women of childbearing potential (WOCBP) or male participants not agreeing to use&#xD;
             highly effective method(s) of birth control throughout the trial and for 4 weeks after&#xD;
             last dose of trial drug as defined in the protocol.&#xD;
&#xD;
          3. Any new development with the participant's disease or condition or any significant&#xD;
             laboratory test abnormality during the course of Trial HZNP-HZN-825-301 that, in the&#xD;
             opinion of the Investigator, would potentially put the subject at unacceptable risk.&#xD;
&#xD;
          4. Pregnant or lactating women.&#xD;
&#xD;
          5. Participants will be ineligible if, in the opinion of the Investigator, they are&#xD;
             unlikely to comply with the trial protocol or have a concomitant disease or condition&#xD;
             that could interfere with the conduct of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arati Kanchi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Horizon Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Horizon Therapeutics</last_name>
    <phone>866-479-6742</phone>
    <email>clinicaltrials@horizontherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRIS Research and Development LLC</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jhon Galindo</last_name>
      <phone>954-476-2338</phone>
      <email>jgalindo@irisrheumatology.com</email>
    </contact>
    <investigator>
      <last_name>Guillermo Valenzuela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DelRicht Clinical Research, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Giorlando</last_name>
      <phone>504-336-2667</phone>
      <email>kgiorlando@delricht.com</email>
    </contact>
    <investigator>
      <last_name>Lesley Saketkoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Physicians Rheumatology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Gonzales</last_name>
      <phone>713-500-7118</phone>
      <email>Patricia.Gonzales@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Maureen Mayes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Reumatologicas</name>
      <address>
        <city>San Miguel De Tucumán</city>
        <state>Tucumán</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Medina</last_name>
      <email>hugomedinadip@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Silvia Yacuzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux, Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justine Landrin</last_name>
      <phone>+33557820495</phone>
      <email>justine.landrin@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Elise Truchetet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kianous Stavros</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelia Mpliakou</last_name>
      <email>litsa_bliaikou@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Lucas Settas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>4763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Jeong Kim</last_name>
      <email>minimay1113@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jae-Bum Jun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>France</country>
    <country>Greece</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>February 20, 2023</last_update_submitted>
  <last_update_submitted_qc>February 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scleroderma</keyword>
  <keyword>Forced vital capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

